CATALYST PHARMACEUTICALS INC. - COMMON STOCK

Catalyst Pharmaceuticals Delivers Strong Second Quarter 2022 Financial Results with Record FIRDAPSE® Revenues and Provides Corporate Update

09 Aug 2022 16:26:30 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 9, 2022

26 Jul 2022 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces Settlement of U.S. Patent Litigation and Resolution of Litigation Challenging Ruzurgi® Approval with Jacobus Pharmaceutical

12 Jul 2022 06:00:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Participate in Two Upcoming Investor Conferences

17 May 2022 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Reports Record First Quarter 2022 Financial Results And Provides Corporate Update

10 May 2022 16:11:56 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Report First Quarter 2022 Financial Results on May 10, 2022

25 Apr 2022 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

16 Mar 2022 16:20:58 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals and KYE Pharmaceuticals Announce a Second Favorable Canadian Federal Court Ruling Setting Aside Approval of Ruzurgi®

11 Mar 2022 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Named Among Forbes 2022 America's Best Small Companies

08 Mar 2022 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2021 Financial Results on March 16, 2022

03 Mar 2022 09:20:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Further Strengthens FIRDAPSE® U.S. Patent Portfolio

02 Mar 2022 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Teams Up with Patients and Advocacy Groups to Ring Nasdaq Opening Bell on Rare Disease Day 2022

24 Feb 2022 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Launch LEMS Aware Podcast on Rare Disease Day 2022

17 Feb 2022 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2021 Total Revenues; Provides 2022 Total Revenue Guidance and Corporate Update

07 Feb 2022 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Reports that the FDA Marketing Approval Previously Granted for Ruzurgi® is No Longer Valid

03 Feb 2022 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces Issuance of Mandate by the U.S. Court of Appeals for the 11th Circuit Directing the District Court Judge in Catalyst's Lawsuit Against the FDA to Grant Summary Judgement in Favor of Catalyst

28 Jan 2022 13:46:42 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces 11th Circuit Court of Appeals Denial of Jacobus Pharmaceutical Company Inc.'s Petition for Rehearing

10 Jan 2022 08:03:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Participate in January 2022 Virtual Investor Conferences

04 Jan 2022 07:30:00 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals Announces DyDo Pharma Initiation of a Phase 3 Study for FIRDAPSE® (amifampridine) in Japan

06 Dec 2021 07:00:01 By Nasdaq GlobeNewswire

Catalyst Pharmaceuticals to Participate at the Piper Sandler 33rd Annual Virtual Healthcare Conference

15 Nov 2021 16:15:00 By Nasdaq GlobeNewswire